Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 113(6): E754-61, 2016 Feb 09.
Article in English | MEDLINE | ID: mdl-26712028

ABSTRACT

Abnormalities in sleep and circadian rhythms are central features of bipolar disorder (BP), often persisting between episodes. We report here, to our knowledge, the first systematic analysis of circadian rhythm activity in pedigrees segregating severe BP (BP-I). By analyzing actigraphy data obtained from members of 26 Costa Rican and Colombian pedigrees [136 euthymic (i.e., interepisode) BP-I individuals and 422 non-BP-I relatives], we delineated 73 phenotypes, of which 49 demonstrated significant heritability and 13 showed significant trait-like association with BP-I. All BP-I-associated traits related to activity level, with BP-I individuals consistently demonstrating lower activity levels than their non-BP-I relatives. We analyzed all 49 heritable phenotypes using genetic linkage analysis, with special emphasis on phenotypes judged to have the strongest impact on the biology underlying BP. We identified a locus for interdaily stability of activity, at a threshold exceeding genome-wide significance, on chromosome 12pter, a region that also showed pleiotropic linkage to two additional activity phenotypes.


Subject(s)
Bipolar Disorder/genetics , Bipolar Disorder/physiopathology , Circadian Rhythm , Sleep , Actigraphy , Chromosomes, Human, Pair 1/genetics , Family , Female , Humans , Inheritance Patterns/genetics , Lod Score , Male , Middle Aged , Pedigree , Phenotype , Quantitative Trait, Heritable
2.
J Oncol Pharm Pract ; 22(3): 548-51, 2016 Jun.
Article in English | MEDLINE | ID: mdl-25791511

ABSTRACT

Pharmacogenetics is a study of how genetic variation of an individual affects the drug response. We report a case of recurrent pancytopenia resulting from maintenance chemotherapy in a patient with acute promyelocytic leukemia and two pharmacogenetic mutations, namely, methylene tetrahydrofolate reductase C677T homozygous mutation and thiopurine methyltransferase mutation.


Subject(s)
Leukemia, Promyelocytic, Acute/genetics , Maintenance Chemotherapy/methods , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Methyltransferases/genetics , Mutation/genetics , Pancytopenia/genetics , Humans , Leukemia, Promyelocytic, Acute/drug therapy , Male , Middle Aged , Pancytopenia/drug therapy , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...